Status:
COMPLETED
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Eligibility Criteria
Inclusion
- Male or female aged 18-65 years (both inclusive)
- Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
- Body mass index 18.0-28.0 kg/m\^2 (both inclusive)
Exclusion
- Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
- Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
- Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
Key Trial Info
Start Date :
July 27 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00961324
Start Date
July 27 2009
End Date
October 26 2009
Last Update
October 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Neuss, Germany, 41460